WO2010122996A1 - 錠剤及びそのための杵 - Google Patents
錠剤及びそのための杵 Download PDFInfo
- Publication number
- WO2010122996A1 WO2010122996A1 PCT/JP2010/056992 JP2010056992W WO2010122996A1 WO 2010122996 A1 WO2010122996 A1 WO 2010122996A1 JP 2010056992 W JP2010056992 W JP 2010056992W WO 2010122996 A1 WO2010122996 A1 WO 2010122996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- shape
- magnesium oxide
- oxide particles
- corner angle
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B30—PRESSES
- B30B—PRESSES IN GENERAL
- B30B15/00—Details of, or accessories for, presses; Auxiliary measures in connection with pressing
- B30B15/06—Platens or press rams
- B30B15/065—Press rams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Definitions
- the present invention relates to a tablet having a specific shape and a bag used for tableting the tablet. More specifically, the present invention relates to a tablet that is a compression-compressed tablet containing a high content of solid particles and has extremely little abrasion and chipping, and a bag for obtaining the tablet. More specifically, the present invention relates to a tablet containing magnesium oxide particles at a high content rate, which is less likely to be worn or chipped.
- a round shape (spherical shape, disc shape) and a deformed shape (football shape, oval shape, triangle shape, etc.) are commercially available.
- a tableting method in which a binder or a disintegrant is blended with magnesium oxide particles is known (Patent Documents 1 and 2). Tablets obtained by these methods have a relatively high content of binder and disintegrant, and therefore the content of magnesium oxide particles is not so high.
- these tablets When these tablets are administered orally, they have the disadvantage that they have a long disintegration time in the oral cavity and are difficult to swallow.
- Patent Document 3 a tablet with a high content of magnesium oxide particles and a short disintegration time has been proposed.
- This tablet has a content of magnesium oxide particles of 88 to 97% by weight, has a disintegration time of 10 seconds or less, and is easy to drink.
- Patent Document 3 describes a tablet with a diameter of 5 to 12 mm and a thickness of 2 to 6 mm, the shape is not particularly described.
- An object of the present invention is to provide a tablet having a high content ratio of solid particles and having excellent shape retention stability with little abrasion and chipping in a tableting process, a tableting process and a transporting process. is there.
- Another object of the present invention is a tablet containing magnesium oxide particles in a high content ratio and having a high hardness, and there is very little abrasion and chipping in the tableting process, transportation process, packaging process and storage, and the form retention It is to provide a tablet excellent in the above and a tableting punch for the same.
- the object of the present invention is a tablet having a cylindrical plate-like basic skeleton and having a dome shape on the upper and lower horizontal planes, and having a specific shape in a cross-sectional shape perpendicular to the center line.
- a tablet having (a) corner angle, (b) corner horizontal distance and (c) cup depth.
- the tablet has a dome shape on the vertical and horizontal planes of the cylindrical plate, and the dome shape on the vertical and horizontal planes is the following (a), ( Requirements for b) and (c) (a) Corner angle is 25 to 45 ° (b) Corner horizontal distance is 0.30 to 1.0 mm (C) Cup depth 0.6-1.2mm
- the tablet characterized by satisfying is provided.
- the wrinkle for tableting the solid particle which satisfies the requirements of following (a), (b) and (c) is provided.
- the tablet is (1) (a) The corner angle is 28 to 40 °, (2) (b) The corner horizontal distance is 0.35 to 0.85 mm. (3) (c) the cup depth is 0.65 to 1.1 mm, (4) The length (diameter) of the horizontal plane in the right cross-sectional shape is 7 to 11 mm, (5)
- the main component is particles of magnesium oxide represented by the following formula (1).
- the content ratio of the magnesium oxide particles is 85 to 95% by weight, (7) Mainly comprising magnesium oxide particles having an average secondary particle size of 0.5 to 25 ⁇ m, (8) for oral administration; (9) It is used for loosening, (10) used for laxative and oral administration; It is desirable that the bag of the present invention is for tableting magnesium oxide particles.
- a tablet containing a high content of solid particles, particularly magnesium oxide particles, and compressed and compressed and by specifying the shape of the compressed tablet, the compression process, the transport process, and the storage In the process, the packaging process, the sales process, and the like, it is possible to provide a tablet having extremely low shape wear stability and excellent chip retention stability.
- the magnesium oxide particle-containing tablet according to the present invention can have a high content ratio of magnesium oxide particles, and is extremely excellent in shape stability, and when orally administered, the disintegration time is very short and easy to drink. Has advantages.
- FIG. 1 shows a cross-sectional structure of a punch composed of an upper punch, a mortar and a lower punch for tableting the tablet of the present invention.
- FIG. 1 shows a vertical cross-sectional structure along the center line 1 in the cylindrical shape of the tablet of the present invention.
- the cross-sectional structure in the vertical direction along the center line of the tablet of the present invention (hereinafter sometimes simply referred to as “cross-sectional shape”) is intended for the left and right with the center line 1 as the central axis.
- the cylindrical plate shape has a quadrilateral skeleton formed by four sides of an upper horizontal plane 2-a, a lower horizontal plane 2-b, a peripheral side surface 3-a, and a peripheral side surface 3-b, and the upper horizontal plane of the basic skeleton.
- a dome shape is formed on 2-a and a dome shape is also formed on the lower horizontal surface 2-b.
- the dome shape on the upper horizontal surface and the dome shape on the lower horizontal surface have the same shape in the vertical direction.
- the tablet of the present invention has the following features (a) to (e) in cross-sectional shape.
- (A) having a quadrilateral basic skeleton based on a cylindrical plate shape;
- the basic skeleton part has a round plate shape)
- the angle ⁇ (referred to as “corner angle”) is 25 to 45 ° from the horizontal plane formed by the dome-shaped linear side 8 from both ends of the upper horizontal plane 2-a.
- the distance 9 (referred to as “corner horizontal distance”) obtained by projecting the length of the straight side 8 with the corner angle onto the upper horizontal plane is 0.35 to 0.85 mm;
- the length 7 (referred to as “cup depth”) of the center line from the upper horizontal plane to the apex of the dome shape is 0.65 to 1.1 mm;
- the dome shape formed on the upper dome horizontal plane 4-a is preferably a part of a circle having a single curvature R (referred to as “curvature R”),
- the diameter (radius) of the curvature R is advantageously 7 to 25 mm, preferably 8 to 22 mm.
- the tablet of the present invention is characterized in that the cross-sectional shape has the shape and length shown in the above (a) to (e).
- the corner angle ⁇ is 25 to 45 °, preferably 28 to 40 °, particularly preferably 29 to 33 °, and the side 8 from the end of the horizontal plane forming the corner angle is linear, It is important that the linear length is a certain length.
- the cross-sectional shape of the tablet of the present invention is such that the dome shape formed on the upper and lower horizontal planes is a straight portion (straight side 8) from the end of the horizontal plane and a part of a circle having a curvature R. It is characterized by having a two-stage structure.
- the tablet of the present invention has a cross-sectional shape in which the corner horizontal distance 9 is 0.3 to 1.0 mm, preferably 0.35 to 0.85 mm.
- the cup depth 7 is 0.6 to 1.2 mm, preferably 0.65 to 1.1 mm.
- the tablet of the present invention is mainly composed of solid particles, and is intended for tablets each having a weight of about 200 mg to about 600 mg.
- the size of the tablet of the present invention can be changed by changing the thickness and diameter of the tablet.
- the tablet diameter 5 (the length of the upper and lower horizontal surfaces) is 6 to 14 mm, preferably 7 to 11 mm, and the thickness 6 is 4 to 6 mm, preferably 4.2 to 5.6 mm. .
- the diameter 5 and the thickness 6 may be appropriately determined from the above ranges based on the desired weight per tablet.
- the tablet of the present invention contains solid particles as a main component and is suitable for compression molding of the particle powder, and is particularly suitable for a powder compression molding of magnesium oxide particles as a main component.
- the tablet mainly composed of magnesium oxide particles will be described.
- the magnesium oxide particles are suitably contained in the tablet as a main component, for example, 80% by weight or more, preferably 85 to 95% by weight, particularly preferably 87 to 93% by weight.
- Magnesium oxide particles are an active ingredient per se, and the higher the content per tablet, the smaller the size and number of tablets taken at one time.
- Magnesium oxide particles may be particles of a compound represented by the following formula (1) chemically. In other words, a small amount of zinc dissolved in magnesium oxide may be used. (Mg 1-x Zn x ) 0 (1) Here, x is in the range of 0 to 0.3, preferably 0 to 0.2.
- magnesium oxide particles having an average secondary particle diameter of 0.5 to 25 ⁇ m, preferably 0.5 to 10 ⁇ m, particularly preferably 1 to 7 ⁇ m, measured by a laser diffraction scattering method.
- the average secondary particle diameter of magnesium oxide is related to the high content ratio of magnesium oxide particles in the tablet and the hardness, abrasion and cutting of the tablet, and is preferably within the above range. is there.
- Tablets mainly composed of magnesium oxide particles can be obtained by appropriately selecting the types and amounts of binders and disintegrants as additives, so that there is less wear and tearing, and the disintegration time is short when administered.
- binders and disintegrants as additives, so that there is less wear and tearing, and the disintegration time is short when administered.
- crystalline cellulose or starch for example, corn starch
- 1 to 10% by weight, preferably 1 to 8% by weight is blended in the amount of the tablet.
- the disintegrant croscarmellose sodium, carmellose calcium or carboxystarch sodium is preferable, and croscarmellose sodium is particularly preferable.
- the disintegrant is added in an amount of 1 to 3.5% by weight, preferably 1 to 3% by weight per tablet.
- the magnesium oxide particles having the average secondary particle size described above are powdered or granulated, and mixed with a binder and a disintegrant. What is necessary is just to compress and compress into powder (or mixed granule form), and this may become a tablet of a predetermined shape.
- the wrinkles used for tableting are adjusted in the corner angle, the corner horizontal distance and the cup depth at the tips of the upper and lower punches so as to have the shape of the tablet of the present invention. Is used.
- the tablet mainly composed of magnesium oxide particles of the present invention can be molded at a relatively low pressure by setting each of the magnesium oxide particles, the binder and the disintegrant in the above ranges, and wear of the tablet punch The obtained tablets also have very little wear and tearing.
- a bowl shape for tableting a tablet having a specific shape as described above is provided.
- FIG. 2 shows an upper punch 10, a mortar 11 and a lower punch 12 for tableting.
- the shape of the tip portion (10-a) of the upper punch 10 is a reverse concave shape so that the portion above the upper horizontal surface of the tablet shown in FIG. 1 is formed. That is, it is a reverse concave shape so that a tablet having a specific corner angle, corner horizontal distance and cup depth can be obtained.
- the tip part (12-a) of the lower punch is concave so that the part below the lower horizontal surface of the tablet shown in FIG. 1 is formed.
- the mortar 11 has a cylindrical cavity having a long diameter corresponding to the round shape of the tablet.
- the shape of the ridge is such that the tip portion (10-a) of the upper heel and the tip portion (12-a) of the lower heel are in a generally used heel structure, except for the tablet shape of the present invention. Things are used.
- the angle of the corner is set to three levels of 15 °, 30 ° and 45 °, the cup depth is changed variously, and the tablet size is further adjusted to 250 mg and 330 mg formulations.
- wrinkles having the shapes shown in Table 1 below were designed and prepared.
- “single corner angle R” means a shape having a corner angle as shown in FIG. 1 and having a dome-shaped curve at the top and a curvature (R) having a single curvature. To do.
- the saddle shape is “single R (comparative)” because the dome-shaped curve has a curvature R directly from a horizontal horizontal plane that does not have a corner angle (and therefore does not have a corner horizontal distance). It means that the shape is formed.
- the 330 mg formulation was prepared by mixing 20 kg magnesium oxide particles, 1.39 kg crystalline cellulose, 0.67 kg croscarmellose sodium and 0.42 kg corn starch in a container-type mixer, and then producing granules using a roll molding granulator. . 22.48 kg of this granule having a granule particle size of 0.3 to 0.4 mm and 0.24 kg of calcium stearate were mixed in a container type mixer to obtain granules for tableting.
- Examples 1 to 4 and Comparative Examples 1 and 2 The 250 mg formulation uses a rotary tableting machine [Mori-Korsch's rotary press PH-300, Kikusui's small high-speed tableting machine VIRGO] as tableting conditions. Compression molding with numbers. On the other hand, a compression molded product using a single R punch was used as a comparison. The tablet was adjusted to have a mass of 287 mg and a tablet thickness of 4.4 mm, and the tablet physical properties are shown in Table 2.
- Examples 5 to 7 and Comparative Examples 3 and 4 The 330 mg formulation was compression molded at a rotating disk rotation number of 35 rpm under the same tableting conditions as in Examples 1 to 4. The tablet was adjusted to have a mass of 377 mg and a tablet thickness of 4.7 mm, and the tablet physical properties are shown in Table 3.
- Example 8 to 11 and Comparative Examples 5 and 6 The 500 mg preparation was compression molded at a rotation speed of 35 rpm under the same tableting conditions as in Examples 1 to 4. The tablet was adjusted to have a mass of 580 mg and a tablet thickness of 5.1 mm, and the physical properties of the tablets are shown in Table 4.
- Example 12 to 14 Stabilization tests were performed using the 250 mg, 330 mg and 500 mg formulations molded in Examples 1, 5 and 8. The test was carried out in a glass bottle (sealed state) for 1 month under storage conditions of 40 ° C. The results are shown in Table 5.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
(a)隅角角度が25~45゜
(b)隅角水平距離が0.30~1.0mm
(c)カップ深さが0.6~1.2mm
を満足することを特徴とする錠剤が提供される。
(a)隅角角度が25~45゜
(b)隅角水平距離が0.30~1.0mm
(c)カップ深さが0.6~1.2mm
さらに、本発明において錠剤は、
(1)(a)隅角角度が28~40°であること、
(2)(b)隅角水平距離が0.35~0.85mmであること、
(3)(c)カップ深さが0.65~1.1mmであること、
(4)直角断面形状における水平面の長さ(径)が7~11mmであること、
(5)下記式(1)で表わされる酸化マグネシウムの粒子を主成分とすること、
(Mg1-x Znx)0 (1)
(ただしxは0~0.3を示す)
(6)酸化マグネシウムの粒子の含有割合が85~95重量%であること、
(7)平均2次粒子径が0.5~25μmの酸化マグネシウムの粒子を主成分とすること、
(8)経口投与するためのものであること、
(9)緩下用に使用されるものであること、
(10)緩下用且つ経口投与のために使用されること、
が望ましく、また本発明の杵は、酸化マグネシウム粒子を製錠化するためのものであることが望ましい。
図1は、本発明の錠剤の円柱形状における中心線1に沿って垂直方向の断面構造を示すものである。図1に示すように、本発明の錠剤の中心線に沿って垂直方向の断面構造(以下単に“断面形状”ということがある)は、中心線1を中心軸として左右が対象であり、また円柱板状は、上部水平面2-a、下部水平面2-b、周囲側面3-aおよび周囲側面3-bの4つの辺から形成される4辺形を基本骨格とし、この基本骨格の上部水平面2-a上にドーム型形状および下部水平面2-b上にもドーム型形状を有している。この上部水平面上のドーム型形状と下部水平面上のドーム型形状は上下方向で対象に同じ形状を有している。
(a)円柱板状に基づく4辺形の基本骨格を有すること、
(基本骨格部分は丸い板状形状である)
(b)その上部水平面2-aの両端部からドーム型形状の直線状の辺8がなす水平面から角度θ(“隅角角度”という)が25~45°であること、
(c)前記隅角角度の直線状の辺8の長さを、上部水平面に投影した距離9(“隅角水平距離”という)が0.35~0.85mmであること、
(d)上部水平面からのドーム型形状の頂点までの中心線の長さ7(“カップ深さ”という)が0.65~1.1mmであること、
(e)中心線1を中心軸として左右対象であり、また上部水平面上と下部水平面上におけるドーム型形状は上下対象の形をしていること、
さらに本発明の錠剤は断面形状において、上ドーム水平面4-a上に形成されるドーム型形状は、単一の曲率R(“曲率R”という)を有する円形の一部であることが望ましく、その曲率Rの径(半径)は、7~25mm、好ましくは8~22mmであるのが有利である。
そのうち、隅角角度θが25~45°、好ましくは28~40°、特に好ましくは29~33°であり、この隅角角度を形成する水平面端部からの辺8が直線状であり、その直線状の長さが一定の長さであることが肝要である。
(Mg1-x Znx)0 (1)
ここでxは0~0.3、好ましくは0~0.2の範囲である。
かくして本発明によれば、前記した特定形状の錠剤を製錠化するための杵形状が提供される。
実施例において、錠剤の(a)硬度、(b)崩壊時間、(c)摩損度および(d)錠剤厚みは以下に記載する測定法によって測定された値を意味する。
(a)硬度
錠剤硬度計 DC-50(岡田精工(株))を用いて、錠剤硬度を測定した。
(b)崩壊時間
「第15局改正日局試験法、一般試験法・崩壊試験法」に準拠し、試験液は水を用いた。
(c)摩損度
全質量が6.5gにできるだけ近い量に相当する錠数を試験試料とし、100回転(24~26回転/分)後、摩損度(初期質量に対する減少質量の百分率)を算出した。
「第15局改正日局試験法、参考情報・錠剤の摩損度試験法」に準拠。
摩損度(%)=(摩損前の錠剤初期質量(g)-摩損後の錠剤質量(g))×100
摩損前の錠剤初期質量(g)
(d)錠剤厚み
シックネスゲージ(新潟精機)を用いて、錠剤厚みを測定した。
本発明の杵形状の有効性を確認するため、隅角角度を15°、30°および45°の3水準とし、またカップ深さを種々変更し、さらに錠剤の大きさを250mg製剤、330mg製剤および500mg製剤の3種とするために下記表1に示した形状の杵をデザイン化し調製した。
なお表中「隅角単R」とは、図1に示すように隅角角度を有し、かつ上部がドーム型曲線でその曲率(R)が単一の曲率を有する形状であることを意味する。
また表2~表4において杵形状が「単R(比較)」とあるのは、隅角角度を有せず(従って隅角水平距離も存在しない)水平水平面から直接ドーム型曲線が曲率Rで形成された形状であることを意味する。
実験用試料として下記3種の組成よりなる試料を調製した。酸化マグネシウム粒子は平均2次粒子径が6.5μmのものを使用した。
(1)250mg製剤;
250mg製剤は、酸化マグネシウム粒子20Kg、結晶セルロース1.44Kg、クロスカルメロースナトリウム0.72Kg、トウモロコシデンプン0.40Kgをコンテナー型混合器にて混合後、ロール成型型造粒機にて顆粒を製造した。顆粒粒径0.3~0.4mmの本顆粒22.56Kgとステアリン酸カルシウム0.24Kgをコンテナー型混合機にて混合し、打錠用顆粒とした。
(2)330mg製剤;
330mg製剤は、酸化マグネシウム粒子20Kg、結晶セルロース1.39Kg、クロスカルメロースナトリウム0.67Kg、トウモロコシデンプン0.42Kgをコンテナー型混合器にて混合後、ロール成型型造粒機にて顆粒を製造した。顆粒粒径0.3~0.4mmの本顆粒22.48Kgとステアリン酸カルシウム0.24Kgをコンテナー型混合機にて混合し、打錠用顆粒とした。
(3)500mg製剤;
500mg製剤は、酸化マグネシウム粒子20Kg、結晶セルロース1.38Kg、クロスカルメロースナトリウム0.69Kgをコンテナー型混合器にて混合後、ロール成型型造粒機にて顆粒を製造した。顆粒粒径0.3~0.4mmの本顆粒22.07Kgとステアリン酸カルシウム0.23Kgをコンテナー型混合機にて混合し、打錠用顆粒とした。
250mg製剤は、打錠条件として、ロータリー式打錠機[Mori-Korsch製のロータリープレスPH-300、菊水製の小型高速式錠剤機VIRGO]を用い、杵1本立、オープンフィードシュー、回転盤回転数で圧縮成型した。一方で、単R杵を用いた圧縮成形品を比較とした。
なお、1錠中の質量287mg、錠剤厚み4.4mmに調整し、錠剤物性結果は表2に示した。
330mg製剤は、実施例1~4と同様な打錠条件下、回転盤回転数35rpmで圧縮成形した。なお、1錠中の質量377mg、錠剤厚み4.7mmに調整し、錠剤物性結果は表3に示した。
500mg製剤は、実施例1~4と同様な打錠条件下、回転盤回転数35rpmで圧縮成形した。なお、1錠中の質量580mg、錠剤厚み5.1mmに調整し、錠剤物性結果は表4に示した。
実施例1、5および8で成形した250mg製剤、330mg製剤および500mg製剤を用い安定化試験を行った。試験は保存条件40℃にて1ヶ月間、ガラス瓶(密栓状態)中で行った。その結果を表5に示した。
2-a 上部水平面
2-b 下部水平面
3-a 周囲側面
3-c 周囲側面
4-a 上ドーム水平面
4-b 下ドーム水平面
5 直径
6 厚み
7 カップ深さ
8 直線状の辺
9 隅角水平距離
10 上杵
10-a 上杵の先端部
11 臼
12 下杵
12-a 下杵の先端部
θ 隅角角度
R ドーム型曲線
Claims (13)
- 円柱板状の上下水平面にドーム型形状を有する錠剤であって、その上下水平面におけるドーム型形状は、円柱板状の中心線の直角断面形状において、下記(a)、(b)および(c)の要件、
(a)隅角角度が25~45゜
(b)隅角水平距離が0.30~1.0mm
(c)カップ深さが0.6~1.2mm
を満足することを特徴とする錠剤。 - (a)隅角角度が28~40゜である請求項1記載の錠剤。
- (b)隅角水平距離が0.35~0.85mmである請求項1記載の錠剤。
- (c)カップ深さが0.65~1.1mmである請求項1記載の錠剤。
- 直角断面形状における水平面の長さ(径)が7~11mmである請求項1記載の錠剤。
- 下記式(1)で表わされる酸化マグネシウムの粒子を主成分とする請求項1記載の錠剤。
(Mg1-x Znx)0 (1)
(ただしxは0~0.3を示す) - 酸化マグネシウムの粒子の含有割合が85~95重量%である請求項1記載の錠剤。
- 平均2次粒子径が0.5~25μmの酸化マグネシウムの粒子を主成分とする請求項1記載の錠剤。
- 請求項1~8のいずれかに記載された経口投与するための錠剤。
- 請求項6~8のいずれかに記載された緩下用に使用するための錠剤。
- 請求項6~8のいずれかに記載された錠剤の緩下用且つ経口投与のための使用するための錠剤。
- 下記(a)、(b)および(c)の要件を満足する固体粒子を錠剤化するための杵。
(a)隅角角度が25~45゜
(b)隅角水平距離が0.30~1.0mm
(c)カップ深さが0.6~1.2mm - 酸化マグネシウムの粒子を製錠化するための請求項12記載の杵。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10767053.1A EP2422771A4 (en) | 2009-04-22 | 2010-04-20 | TABLET AND PILONS FOR THIS |
KR1020117026782A KR101388734B1 (ko) | 2009-04-22 | 2010-04-20 | 정제 및 그것을 위한 펀치 |
SG2011072246A SG175053A1 (en) | 2009-04-22 | 2010-04-20 | Tablet and pestles therefor |
CA2758714A CA2758714C (en) | 2009-04-22 | 2010-04-20 | Tablet and pestle therefor |
US13/264,163 US8911779B2 (en) | 2009-04-22 | 2010-04-20 | Tablet and pestle therefor |
JP2011510321A JP5564040B2 (ja) | 2009-04-22 | 2010-04-20 | 錠剤 |
RU2011147183/15A RU2517130C2 (ru) | 2009-04-22 | 2010-04-20 | Таблетка и пуансон для нее |
CN2010800180076A CN102413818A (zh) | 2009-04-22 | 2010-04-20 | 片剂及其杵 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-104097 | 2009-04-22 | ||
JP2009104097 | 2009-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010122996A1 true WO2010122996A1 (ja) | 2010-10-28 |
Family
ID=43011113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/056992 WO2010122996A1 (ja) | 2009-04-22 | 2010-04-20 | 錠剤及びそのための杵 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8911779B2 (ja) |
EP (1) | EP2422771A4 (ja) |
JP (1) | JP5564040B2 (ja) |
KR (1) | KR101388734B1 (ja) |
CN (1) | CN102413818A (ja) |
CA (1) | CA2758714C (ja) |
MY (1) | MY154023A (ja) |
RU (1) | RU2517130C2 (ja) |
SG (2) | SG10201401678TA (ja) |
TW (1) | TWI488621B (ja) |
WO (1) | WO2010122996A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015072442A1 (ja) | 2013-11-12 | 2015-05-21 | 第一三共株式会社 | 錠剤 |
US9488538B2 (en) | 2012-01-31 | 2016-11-08 | Smart Skin Technologies, Inc. | Pressure mapping and orientation sensing system |
JPWO2019004155A1 (ja) * | 2017-06-27 | 2020-04-23 | 第一三共株式会社 | 錠剤 |
US10883827B2 (en) | 2016-12-20 | 2021-01-05 | Smart Skin Technologies Inc. | Packaging device for measuring motion in manufacture |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3111957B1 (en) * | 2014-02-25 | 2018-11-21 | Konoshima Chemical Co., Ltd. | Magnesium oxide granules for pharmaceutical applications or food additive applications |
JP7149169B2 (ja) * | 2018-09-21 | 2022-10-06 | 株式会社Screenホールディングス | 錠剤印刷装置および錠剤印刷方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4937026B1 (ja) * | 1969-03-07 | 1974-10-04 | ||
JP2000001428A (ja) * | 1998-04-16 | 2000-01-07 | Nippon Shinyaku Co Ltd | 錠剤及び製造法 |
JP2003146889A (ja) * | 2001-08-27 | 2003-05-21 | Kyowa Chem Ind Co Ltd | 制酸・緩下用錠剤 |
WO2007007659A1 (ja) * | 2005-07-08 | 2007-01-18 | Takeda Pharmaceutical Company Limited | 錠剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5527228B2 (ja) | 1972-08-18 | 1980-07-18 | ||
ZA813205B (en) | 1980-12-05 | 1983-03-30 | Smith Kline French Lab | Dosage units |
CA1195251A (en) * | 1981-07-20 | 1985-10-15 | Anthony B.J. Eoga | Convex tablet configuration |
JPH0940561A (ja) | 1995-08-02 | 1997-02-10 | Fujitsukusu Kk | 瀉下剤 |
JP2001048792A (ja) | 1998-11-26 | 2001-02-20 | Fujix Kk | 瀉下剤 |
WO2003018034A1 (fr) | 2001-08-27 | 2003-03-06 | Kyowa Chemical Industry Co., Ltd. | Comprimes antiacides et laxatifs |
JP4937026B2 (ja) * | 2006-12-28 | 2012-05-23 | Sriスポーツ株式会社 | ゴルフボール |
BR112012005163A2 (pt) * | 2009-09-08 | 2016-05-03 | Kyowa Chem Ind Co Ltd | comprimido antiácido e laxante compreendendo partículas de óxido de magnésio, processo para produzir um comprimido antiácido e laxante, e, uso do comprimido |
-
2010
- 2010-04-20 RU RU2011147183/15A patent/RU2517130C2/ru not_active IP Right Cessation
- 2010-04-20 SG SG10201401678TA patent/SG10201401678TA/en unknown
- 2010-04-20 EP EP10767053.1A patent/EP2422771A4/en not_active Withdrawn
- 2010-04-20 CN CN2010800180076A patent/CN102413818A/zh active Pending
- 2010-04-20 WO PCT/JP2010/056992 patent/WO2010122996A1/ja active Application Filing
- 2010-04-20 KR KR1020117026782A patent/KR101388734B1/ko not_active IP Right Cessation
- 2010-04-20 SG SG2011072246A patent/SG175053A1/en unknown
- 2010-04-20 CA CA2758714A patent/CA2758714C/en not_active Expired - Fee Related
- 2010-04-20 US US13/264,163 patent/US8911779B2/en not_active Expired - Fee Related
- 2010-04-20 JP JP2011510321A patent/JP5564040B2/ja active Active
- 2010-04-20 MY MYPI2011004764A patent/MY154023A/en unknown
- 2010-04-21 TW TW099112472A patent/TWI488621B/zh not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4937026B1 (ja) * | 1969-03-07 | 1974-10-04 | ||
JP2000001428A (ja) * | 1998-04-16 | 2000-01-07 | Nippon Shinyaku Co Ltd | 錠剤及び製造法 |
JP2003146889A (ja) * | 2001-08-27 | 2003-05-21 | Kyowa Chem Ind Co Ltd | 制酸・緩下用錠剤 |
WO2007007659A1 (ja) * | 2005-07-08 | 2007-01-18 | Takeda Pharmaceutical Company Limited | 錠剤 |
Non-Patent Citations (2)
Title |
---|
KAZUO KIGASAWA ET AL.: "Pharmaceutical Studies on Physical Properties of Solid Form Drugs. III. Influence of Tablet Formula and Tablet Shape on Distribution of Boring Hardness inside Tablet", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 95, no. 7, 1975, pages 769 - 773, XP003002901 * |
MASAO UENO: "Kine Usu no Sekkei to Seisaku", PHARM TECH JAPAN, vol. 11, no. 5, 1995, pages 549 - 552, XP008152569 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9488538B2 (en) | 2012-01-31 | 2016-11-08 | Smart Skin Technologies, Inc. | Pressure mapping and orientation sensing system |
EP3974038A1 (en) | 2012-01-31 | 2022-03-30 | Smart Skin Technologies Inc. | Pressure mapping and orientation sensing system |
WO2015072442A1 (ja) | 2013-11-12 | 2015-05-21 | 第一三共株式会社 | 錠剤 |
JPWO2015072442A1 (ja) * | 2013-11-12 | 2017-03-16 | 第一三共株式会社 | 錠剤 |
US10883827B2 (en) | 2016-12-20 | 2021-01-05 | Smart Skin Technologies Inc. | Packaging device for measuring motion in manufacture |
JPWO2019004155A1 (ja) * | 2017-06-27 | 2020-04-23 | 第一三共株式会社 | 錠剤 |
JP7203726B2 (ja) | 2017-06-27 | 2023-01-13 | 第一三共株式会社 | 錠剤 |
Also Published As
Publication number | Publication date |
---|---|
SG175053A1 (en) | 2011-11-28 |
EP2422771A4 (en) | 2014-02-19 |
CA2758714C (en) | 2016-08-02 |
SG10201401678TA (en) | 2014-06-27 |
RU2011147183A (ru) | 2013-05-27 |
RU2517130C2 (ru) | 2014-05-27 |
MY154023A (en) | 2015-04-30 |
TWI488621B (zh) | 2015-06-21 |
US8911779B2 (en) | 2014-12-16 |
CA2758714A1 (en) | 2010-10-28 |
KR20120006541A (ko) | 2012-01-18 |
CN102413818A (zh) | 2012-04-11 |
TW201041574A (en) | 2010-12-01 |
KR101388734B1 (ko) | 2014-04-25 |
EP2422771A1 (en) | 2012-02-29 |
US20120034301A1 (en) | 2012-02-09 |
JP5564040B2 (ja) | 2014-07-30 |
JPWO2010122996A1 (ja) | 2012-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5564040B2 (ja) | 錠剤 | |
JP5696050B2 (ja) | 制酸・緩下用錠剤 | |
AU785135B2 (en) | Granules based on starch and lactose | |
IL142788A (en) | A pill that breaks down quickly | |
JP2008543767A5 (ja) | ||
EP1421944B1 (en) | Antacid and laxative tablet comprising magnesium oxide | |
CA2728436C (en) | Directly compressible and rapidly disintegrating tablet matrix | |
CN102526748B (zh) | 含有缬沙坦、氢氯噻嗪和苯磺酸氨氯地平的口服片剂 | |
JP4015485B2 (ja) | 制酸・緩下用錠剤 | |
JP5034226B2 (ja) | 配合成分が安定化された固形製剤 | |
Jagtap et al. | Development of directly compressible ascorbic acid tablet using novel excipients | |
JP2023014238A (ja) | 錠剤の製造方法及び造粒粒子群 | |
JP2011184328A (ja) | 医薬品又は食品用の粉体圧縮成形物、及びその製造方法 | |
JP2010248157A (ja) | 魚鱗粉末高濃度含有錠剤 | |
JP2016121078A (ja) | 固形医薬組成物及びその製造方法 | |
JPS58164519A (ja) | 滑沢剤およびそれを用いた固形製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080018007.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10767053 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011510321 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13264163 Country of ref document: US Ref document number: 2758714 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7744/CHENP/2011 Country of ref document: IN Ref document number: 2010767053 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117026782 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011147183 Country of ref document: RU Kind code of ref document: A |